In @eahad.bsky.social's latest podcast,
@majfbirkedal.bsky.social discusses using a subcutaneous drug delivery device to reduce treatment-related #pain in children with #haemophiliaA on #emicizumab. Read her paper in The Journal of Haemophilia Practice sciendo.com/article/10.2...
#HemeSky #MedSky
@majfbirkedal.bsky.social discusses using a subcutaneous drug delivery device to reduce treatment-related #pain in children with #haemophiliaA on #emicizumab. Read her paper in The Journal of Haemophilia Practice sciendo.com/article/10.2...
#HemeSky #MedSky
September 4, 2025 at 10:41 AM
In @eahad.bsky.social's latest podcast,
@majfbirkedal.bsky.social discusses using a subcutaneous drug delivery device to reduce treatment-related #pain in children with #haemophiliaA on #emicizumab. Read her paper in The Journal of Haemophilia Practice sciendo.com/article/10.2...
#HemeSky #MedSky
@majfbirkedal.bsky.social discusses using a subcutaneous drug delivery device to reduce treatment-related #pain in children with #haemophiliaA on #emicizumab. Read her paper in The Journal of Haemophilia Practice sciendo.com/article/10.2...
#HemeSky #MedSky
Discover the latest advancements in Acquired Haemophilia A with the latest e-learning module on the EAHAD Academy! Join expert Rebecca Kruse-Jarres as she explores current practices and future directions in this comprehensive session. 🎥 academy.eahad.org/eahad/2025/e... #HaemophiliaA
March 14, 2025 at 11:59 AM
Discover the latest advancements in Acquired Haemophilia A with the latest e-learning module on the EAHAD Academy! Join expert Rebecca Kruse-Jarres as she explores current practices and future directions in this comprehensive session. 🎥 academy.eahad.org/eahad/2025/e... #HaemophiliaA
#Roche's #Hemlibra treatment for #haemophiliaA is one of its top-selling drugs, making almost $5 billion last year, and the company has now lined up what looks like an impressive successor.
Roche's Hemlibra follow-up set for phase 3 in haemophilia A
Roche has positive data with its follow-up to haemophilia A blockbuster Hemlibra, but a rival drug from Novo Nordisk is looming.
buff.ly
June 23, 2025 at 1:00 PM
#Roche's #Hemlibra treatment for #haemophiliaA is one of its top-selling drugs, making almost $5 billion last year, and the company has now lined up what looks like an impressive successor.
#Novo #obesity #patentprotection #Wegovy #weightloss #Ozempic #diabetes #CagriSema #Foundayo #Haematology #haemophiliaA #Frehemgo #sicklecelldisease #PNH #blooddisorders #endocrinedisorders #liverdiseases #cardiovasculardisease #consumerRx #pain #addiction #menshealth #womenshealth
zurl.co/Lmdba
zurl.co/Lmdba
Under pressure, Novo lays out blockbuster launch plans
Novo has revealed a plan to launch five or more blockbusters between now and 2030 that it hopes will grow annual revenues by around $23bn.
zurl.co
September 24, 2026 at 8:52 AM
A new study on cost-effective care for haemophilia A in the United States, co-authored by YHEC's Amy Dymond and Will Green, is available. It compares efanesoctocog alfa with extended half-life factor VIII prophylaxis.
www.yhec.co.uk/resources-an...
#HaemophiliaA #BleedingDisorders #RareDiseases
www.yhec.co.uk/resources-an...
#HaemophiliaA #BleedingDisorders #RareDiseases
November 13, 2025 at 12:03 PM
A new study on cost-effective care for haemophilia A in the United States, co-authored by YHEC's Amy Dymond and Will Green, is available. It compares efanesoctocog alfa with extended half-life factor VIII prophylaxis.
www.yhec.co.uk/resources-an...
#HaemophiliaA #BleedingDisorders #RareDiseases
www.yhec.co.uk/resources-an...
#HaemophiliaA #BleedingDisorders #RareDiseases
#Novo has moved a step closer to #EU approval of its long-acting #haemophiliaA therapy, #Frehemgo, after it was backed by the #EMA's human medicines committee.
pharmaphorum.com/news/chmp-ba...
pharmaphorum.com/news/chmp-ba...
CHMP backs Novo's haemophilia A drug Frehemgo
Novo has moved a step closer to EU approval of its long-acting haemophilia A therapy, Frehemgo, which could be a future blockbuster.
pharmaphorum.com
September 18, 2026 at 12:10 PM
#Novo has moved a step closer to #EU approval of its long-acting #haemophiliaA therapy, #Frehemgo, after it was backed by the #EMA's human medicines committee.
pharmaphorum.com/news/chmp-ba...
pharmaphorum.com/news/chmp-ba...